 |
 |
|
|
RESÚMENES JULIO 2008 |
Schizophrenia-Psychotic Disorders & Antipsychotics
(Haga un click en la información del journal
para acceder al resúmen)
5 – doble-ciego o
metanálisis; 4 – subanálisis o simple ciego; 3 –
revisión, abierto, básico; 2 – casos; 1 – opinión
GRATIS = Texto gratuito en algunos países de la región iberoamericana
(algunos artículos requieren ir a la tabla de contenidos del número actual de
la revista)
3 - Valproate as prophylaxis for clozapine-induced
seizures: survey of practice
Anna Sparshatt, Senior Clinical Pharmacist,
Eromona Whiskey, Principal Clinical Pharmacist and
David Taylor
Psychiatric Bulletin (2008)
32: 262-265
3 - Cannabis and
schizophrenia: towards a cannabinoid hypothesis of
schizophrenia
Kirsten
R Müller-Vahl and Hinderk M Emrich
Expert Review of Neurotherapeutics. July 2008, Vol. 8, No. 7, Pages 1037-1048
5< - Selective
Muscarinic Receptor Agonist Xanomeline
as a Novel Treatment Approach for Schizophrenia
Anantha Shekhar, William Z. Potter, Jeffrey Lightfoot, John Lienemann, Sanjay Dubé, , Craig
Mallinckrodt, Frank P. Bymaster, David L. McKinzie, and Christian C. Felder
Am J Psychiatry Published July 1, 2008
3 - Olanzapine, but not haloperidol, enhances PSA-NCAM immunoreactivity in rat prefrontal cortex
Angelisa Frasca, Fabio Fumagalli, Judith ter Horst, Giorgio Racagni, Keith
J. Murphy and Marco A. Riva
The
International Journal of Neuropsychopharmacology
(2008), 11:591-595
3! - Are sexual side effects of prolactin-raising
antipsychotics reducible to serum prolactin?
Henderikus Knegtering, Rob van den Bosch, Stynke Castelein, Richard Bruggeman, Sjoerd Sytema and Jim van Os
Psychoneuroendocrinology. Volume 33, Issue 6, July 2008, Pages 711-717
3 - Antipsychotic-Like Behavioral
Effects and Cognitive Enhancement by a Potent and Selective Muscarinic
M1 Receptor Agonist, AC-260584
Kimberly E. Vanover, Isaac Veinbergs
and Robert E. Davis
Behavioral Neuroscience. Volume
122, Issue 3, June 2008, Pages 570-575
3 - Effects
of hepatic or renal impairment on the pharmacokinetics of aripiprazole
Mallikaarjun S, Shoaf SE, Boulton DW, Bramer SL
Clin Pharmacokinet. 2008;47(8):533-42
3 - The
Impact of Olanzapine on Tardive
Dyskinetic Symptoms in a
Jaspreet S. Brar; Haranath Parepally; Lokaranjit Chalasani; Aziz Gopalani;
Nicole Appel; K.N. Roy Chengappa
Annals of Clinical
Psychiatry, Volume 20, Issue 3 August 2008, pages 139 - 144
3 - Physical
health problems in schizophrenia and other serious mental illnesses
Cherian
Sebastian and M Dominic Beer
Journal
of Psychiatric Intensive Care (2007), 3:101-111
3 - Monthly
Administration of Long-Acting Injectable Risperidone and Striatal Dopamine
D2 Receptor Occupancy for the Management of Schizophrenia
Hiroyuki Uchida,
David C. Mamo, Shitij Kapur, Alain Labelle, Chekkera Shammi, Erik J. L. Mannaert,
Steve W. Mann, and Gary Remington
J Clin Psychiatry
July 15, 2008: e1-e6
5< - Short-Term Testosterone Augmentation in Male
Schizophrenics: A Randomized, Double-Blind, Placebo-Controlled Trial
Ko, Young-Hoon;
Lew, Young-Min; Jung, Sung-Won; Joe, Sook-Haeng; Lee,
Chang-Hyun; Jung, Hyun-Gang; Lee, Moon-Soo
Journal of Clinical
Psychopharmacology. 28(4):375-383,
August 2008
5! - Standard and Higher Dose of Olanzapine
in Patients With Schizophrenia or Schizoaffective
Disorder: A Randomized, Double-Blind, Fixed-Dose Study
Kinon, Bruce J; Volavka,
Jan; Stauffer, Virginia; Edwards, Sara E; Liu-Seifert, Hong; Chen, Lei; Adams,
David H; Lindenmayer, Jean-Pierre; McEvoy, Joseph P; Buckley, Peter F; Lieberman, Jeffrey A;
Meltzer, Herbert Y; Wilson, Daniel R; Citrome, Leslie
Journal of Clinical
Psychopharmacology. 28(4):392-400,
August 2008
3 - Metabolic syndrome in female patients with
schizophrenia treated with second generation antipsychotics: a 3-month
follow-up
V Medved,
M R Kuzman,
Journal of Psychopharmacology. First published on July 17, 2008
3! - Antimanic potency of
typical neuroleptic drugs and affinity for dopamine
D2 and serotonin 5-HT2A receptors – a new analysis of data from the archives
and implications for improved antimanic treatments
P
E Harrison-Read
Journal of Psychopharmacology. First published on July 17, 2008
3! - Neural markers of symptomatic improvement during
antidepressant therapy in severe depression: subgenual
cingulate and visual cortical responses to sad, but
not happy, facial stimuli are correlated with changes in symptom score
P Keedwell,
D Drapier,
Journal of Psychopharmacology. First published on July 17, 2008
3! - Outcomes for schizophrenia patients with clozapine treatment: how good does it get?
A Wheeler, V Humberstone,
and G Robinson
Journal
of Psychopharmacology. First published on July 17, 2008
GRATIS 3! - The Sertindole Safety
Survey: a retrospective analysis under a named patient-use program in
Christophe Lancon, Mondher Toumi,
Christophe Sapin and Karina Hansen
3! -
Coagulation and inflammation markers during atypical or typical antipsychotic
treatment in schizophrenia patients and drug-free first-degree relatives
Edgardo Carrizo,
Virginia Fernández, Jesús
Quintero, Lissette Connell, Zulay
Rodríguez, Mônica Mosquera, Arnaldo Acosta and Trino Baptista
Schizophrenia Research. Volume 103, Issues 1-3,
August 2008, Pages 83-93
3 - The
once-daily human GLP-1 analog, liraglutide,
reduces olanzapine-induced weight gain and glucose
intolerance
Kirsten Lykkegaard, Philip J. Larsen, Niels
Vrang, Camilla Bock, Troels
Bock and Lotte Bjerre
Knudsen
Schizophrenia Research. Volume 103, Issues 1-3,
August 2008, Pages 94-103
4 - Impact
of antipsychotic treatment on nonfasting
triglycerides in the CATIE Schizophrenia Trial phase 1
Jonathan M. Meyer,
Vicki G. Davis, Joseph P. McEvoy, Donald C. Goff,
Henry A. Nasrallah, Sonia M. Davis, Gail L. Daumit, John Hsiao, Marvin S. Swartz, T. Scott Stroup and
Jeffrey A. Lieberman
Schizophrenia Research. Volume 103, Issues 1-3,
August 2008, Pages 104-109
3 - Glucose
abnormalities in the siblings of people with schizophrenia
Emilio Fernandez-Egea, Miguel Bernardo, Eduard Parellada,
Azucena Justicia, Clemente
Garcia-Rizo, Enric Esmatjes, Ignacio Conget and
Brian Kirkpatrick
Schizophrenia Research. Volume 103, Issues 1-3,
August 2008, Pages 110-113
3! -
Psychopathology among offspring of parents with schizophrenia: Relationship to premorbid impairments
Matcheri Keshavan, Debra M. Montrose, Rajaprabhakaran
Rajarethinam, Vaibhav Diwadkar, Konasale Prasad and
John A. Sweeney
Schizophrenia
Research. Volume
103, Issues 1-3, August 2008, Pages 114-120
3! - First-Episode Psychosis: Diagnostic Stability over One and
Two Years
Ulrik Haahr, Svein Friis, Tor K. Larsen,
Ingrid Melle, Jan Olav Johannessen,
Stein Opjordsmoen, Erik Simonsen,
Bjørn Rishovd Rund, Per Vaglum, Thomas McGlashan
Psychopathology
2008;41:322-329
3 -
Associations Between Venous Thromboembolism and Antipsychotics : A Study of the WHO Database of Adverse Drug
Reactions
Hägg S, Bate A, Stahl M, Spigset O
3! - Multiple
Genetic Factors in Olanzapine-Induced Weight Gain in
Schizophrenia Patients: A Cohort Study
Hiroshi Ujike, Akira Nomura, Yukitaka
Morita, Akiko Morio, Yuko Okahisa,
Tatsuya Kotaka, Masafumi
Kodama, Takeshi Ishihara, and Shigetoshi Kuroda
J Clin Psychiatry
July 15, 2008: e1-e7
3 -
Implementation of a Schizophrenia Practice Guideline: Clinical Results
Stefan Weinmann, Susanne Hoerger; Monika
Erath; Reinhold Kilian, Wolfgang Gaebel,
and Thomas Becker
J Clin Psychiatry July 15, 2008: e1-e8
3 - Improvement of Subjective
Well-being and Enduring Symptomatic Remission, A
5-Year Follow-up of First Episode Schizophrenia
L. de Haan, L.
van Nimwegen, T. van Amelsvoort, P. Dingemans, D. Linszen
Pharmacopsychiatry 2008; 41: 125-128
3 - Large
Variability of Aripiprazole and Dehydroaripiprazole Serum Concentrations in
Adolescent Patients with Schizophrenia
Bachmann CJ, Rieger-Gies A, Heinzel-Gutenbrunner M, Hiemke C, Remschmidt H,
Theisen FM
Ther Drug Monit. 2008 Jul 10. [Epub ahead of print]
3 - Are Second Generation Antipsychotics a Distinct
Class?
BONHAM, CAROLINE; ABBOTT, CHRISTOPHER
Journal of Psychiatric Practice. 14(4):225-231, July 2008
3 - Effect of sertindole on QTc interval in patients with schizophrenia
Murad Atmaca, Mustafa Yavuzkir, Osman Mermi, Mehtap
Topuz, Ebru Kanmaz and Ertan Tezcan
Neuroscience Letters.
Volume 442, Issue 1, 5 September 2008, Pages 1-3
3! - Gene polymorphism influencing treatment response in
psychotic patients in a naturalistic setting
Malin Alenius, Mia Wadelius, Marja-Liisa Dahl, Per Hartvig,
Leif Lindström and Margareta Hammarlund-Udenaes
Journal of Psychiatric Research. Volume 42, Issue 11, September 2008, Pages 884-893
3! - Association between age at onset and clinical
features of schizophrenia: The
Suvi Luoma, Helinä Hakko, Taru
Ollinen, Marjo-Riitta Järvelin and Sari
Lindeman
European Psychiatry. Volume 23, Issue 5, August 2008, Pages 331-335
3 - Preference of medicine and patient-reported quality of
life in community-treated schizophrenic patients receiving aripiprazole
vs standard of care Results from the STAR study
David Taylor, Linda Hanssens, Jean-Yves Loze, Miranda Pans, Gilbert L'Italien
and Ronald N. Marcus
European Psychiatry. Volume 23, Issue 5, August 2008, Pages 336-343
3 - Clozapine interacts with
the glycine site of the NMDA receptor:
Electrophysiological studies of dopamine neurons in the rat ventral tegmental area
Lilly Schwieler, Klas
R. Linderholm, Linda K. Nilsson-Todd, Sophie Erhardt and Göran
Engberg
Life Sciences.
Volume 83, Issues 5-6, 1 August 2008, Pages 170-175
3 - Pharmacotherapy of schizophrenia with comorbid substance use disorder — Reviewing the evidence
and clinical recommendations
T. Wobrock and M. Soyka
3< - Combined antipsychotic treatment involving clozapine and aripiprazole
Susanne Englisch and Mathias Zink
3 - Effects of second generation antipsychotics on leptin and ghrelin
Ayşen Esen-Danacı, Aslı
Sarandöl, Fatma Taneli, Fatma Yurtsever
and Nesrin Özlen
3! - Estimating the effects of co-medications on plasma olanzapine concentrations by using a mixed model
Sheila Botts, Francisco J. Diaz, Vincenza Santoro, Edoardo Spina, Maria R.
Muscatello, Myladis Cogollo, Fidel E. Castro and Jose de Leon
3! - Differential striatal
levels of TNF-
, NFκB p65 subunit and dopamine with chronic typical and atypical neuroleptic treatment: Role in orofacial
dyskinesia
Mahendra Bishnoi, Kanwaljit Chopra and Shrinivas K. Kulkarni
3 - Association between dopamine-related polymorphisms
and plasma concentrations of prolactin during risperidone treatment in schizophrenic patients
Norio Yasui-Furukori, Manabu Saito, Shoko Tsuchimine, Taku Nakagami, Yasushi Sato, Norio Sugawara and Sunao Kaneko
3< - Decreased levels of ghrelin,
cortisol, and fasting blood sugar, but not n-octanoylated ghrelin, in Japanese
schizophrenic inpatients treated with olanzapine
Kazuhide Tanaka, Shigeru Morinobu, Mai Ichimura, Akihiro Asakawa, Akio
Inui, Hiroshi Hosoda, Kenji Kangawa
and Shigeto Yamawaki
3 - Acute antipyschotic
efficacy and side effects in schizophrenia: Association with serotonin
transporter promoter genotypes
Vita Dolžan, Alessandro Serretti, Laura Mandelli, Jure Koprivšek, Matej
Kastelic and Blanka Kores Plesničar
5 - A
Multicenter, Randomized, Double-Blind Study of the Effects of Aripiprazole in Overweight Subjects With
Schizophrenia or Schizoaffective Disorder Switched From Olanzapine
John W. Newcomer,
Joao Alberto Campos, Ronald N. Marcus, Christopher Breder,
Robert M. Berman, Wendy Kerselaers, Gilbert J. L'Italien, Marleen Nys, William H. Carson, and Robert D. McQuade
J Clin Psychiatry 2008;69:1046-1056
3 - Effects
of amisulpride on the cognitive function of patients
with schizophrenia who switched from risperidone
Yu-Ting Wang;
Nan-Ying Chiu; Shaw-Hwa Jou;
Yen Kuang Yang; I Hui
Lee; Ching-Cheng Wang; Kao Ching Chen; Yi-Cheng Liao
International
Journal of Psychiatry in Clinical Practice, Volume 12, Issue 3 2008, pages 180
- 186
3! -
Long-term, naturalistic treatment with olanzapine, risperidone, quetiapine, or
haloperidol monotherapy: 24-month results from the
Intercontinental Schizophrenia Outpatient Health Outcomes (IC-SOHO) study
Phil Lee; Chul Eung Kim; Chang Yoon
Kim; Wei-Wen Lin; Hussain
Habil; Yulia Dyachkova; Margaret Mcbride;
Martin Dossenbach
International
Journal of Psychiatry in Clinical Practice, Volume 12, Issue 3 2008, pages 215
- 227
3 - The
clinical use of plasma clozapine levels in a maximum
security setting
Daniel M. Bennett; Margaret Bremner; Colin
Gray
International
Journal of Psychiatry in Clinical Practice, Volume 12, Issue 3 2008, pages 228
- 234
3 -
Effectiveness of a structured diet program in antipsychotic-induced weight gain
in patients with schizophrenia
Nese Direk; Alp Ucok
International
Journal of Psychiatry in Clinical Practice, Volume 12, Issue 3 2008, pages 238
- 240
3 - Serum
levels of aripiprazole and dehydroaripiprazole,
clinical response and side effects
Katrin M. Kirschbaum; Matthias J. M
ller; Jaroslav Malevani; Arian Mobascher;
Carsten Burchardt;
Markus Piel; Christoph Hiemke
World Journal of
Biological Psychiatry, Volume 9, Issue 3 2008, pages 212 - 218
3! - Impact
of Cannabis and Other Drugs on Age at Onset of Psychosis
Ana González-Pinto, Patricia Vega, Berta Ibáñez, Fernando Mosquera, Sara Barbeito, Miguel Gutiérrez, Sonia Ruiz de Azúa, Iván Ruiz, and Eduard Vieta
J Clin Psychiatry
July 29, 2008: e1-e7
3! -
Psychiatric Diagnosis as an Independent Risk Factor for Metabolic Disturbances:
Results From a Comprehensive, Naturalistic Screening
Program
Ruud van Winkel, Jim van Os, Ivan Celic,
Dominique Van Eyck, Martien Wampers,
Andre Scheen, Joseph Peuskens,
and Marc De Hert
J Clin Psychiatry
July 29, 2008: e1-e9
3 - Co-Occurring Depressive Symptoms in the Older Patient
with Schizophrenia
Kasckow, John W; Zisook, Sidney
Drugs & Aging. 25(8):631-647, 2008
GRATIS - ABILIFY® (aripiprazole) Tablets
HIGHLIGHTS OF
PRESCRIBING INFORMATION
3! - BDNF Levels
and Genotype are Associated with Antipsychotic-Induced Weight Gain in Patients
with Chronic Schizophrenia
Xiang Yang Zhang,
Dong Feng Zhou, Gui
Ying Wu, Lian Yuan Cao, Yun
Long Tan, Colin N Haile, Jun Li,
Lin Lu, Therese A Kosten and Thomas R Kosten
Neuropsychopharmacology (2008) 33, 2200–2205
| Regresar a RESÚMENES JULIO 2008 |